IGF-1R targeting increases the antitumor effects of DNA damaging agents in SCLC model: an opportunity to increase the efficacy of standard therapy
Molecular Cancer Therapeutics, May 6, 2013
Ferte C et al. - Insulin-like growth factor receptor-1 (IGF-1R) inhibition could be a relevant therapeutic approach in small cell lung cancer (sclc) given the importance of an IGF-1R autocrine loop and its role in DNA damage repair processes. In conclusion, adding R1507 to the current standard Cisplatin-IR doublet reveals remarkable chemo- and radiosensitizing effects in selected sclc models and warrants to be investigated in the clinical setting.
Alternating Chemotherapy with Amrubicin Plus Cisplatin and Weekly Administration of Irinotecan Plus Cisplatin for Extensive-stage Small Cell Lung Cancer
Anticancer Research, March 13, 2013
Noro R et al. – A phase II study was conducted in order to determine the tumor efficacy and tolerance of alternating chemotherapy for extensive–stage small cell lung cancer (ED–sclc). The novel alternating non–cross–resistant chemotherapy was probably active against ED–sclc and had acceptable toxicities.
Twenty patients with previously-untreated ED-sclc were enrolled in the study.
At least four courses of chemotherapy consisting of alternation of two drug combinations ...
Utility of the Quantitative Ki-67 Proliferation Index and CD56 Together in the Cytologic Diagnosis of Small Cell Lung Carcinoma and Other Lung Neuroendocrine Tumors
Acta Cytologica, April 29, 2013
Zheng G et al. - The authors evaluated CD56 and the quantitative Ki-67 immunohistochemical panel in comparison to synaptophysin and chromogranin, along with cytomorphology to diagnose small cell lung carcinoma (sclc). CD56 and quantitative Ki-67 along with cytomorphology is a robust immunohistochemical panel to differentiate sclc from other neuroendocrine neoplasms and non-small cell lung carcinoma (Nsclc).
New dilemmas in small-cell lung cancer TNM clinical staging
OncoTargets and Therapy, May 17, 2013
Zarogoulidis K et al. - Many patients with limited disease (LD) behave similarly to those with extensive disease (ED) from a prognostic point of view. On the other hand, a proportion of patients with ED small-cell lung cancer (sclc) behave similarly to those with LD. Although stratification of sclc patients in LD and ED is generally satisfactory, the TNM staging system is recommended for more detailed prognostic information and treatment evaluation in these patients.
Free drugs in clinical trials and their potential cost saving impact on the National Health Service: A retrospective cost analysis in Italy
Lung Cancer, May 8, 2013
Grossi F et al. - The cost of new anti-cancer drugs has dramatically increased in recent years, and countermeasures are required in order to limit pharmaceutical expenses. Sponsored clinical trials that provide drugs free of charge may be a useful tool in order to reduce drug costs. The aim of this analysis is to evaluate the effect of clinical trials on pharmaceutical expenditure savings. The participation in sponsored clinical trials in which drugs are provided free of charge ...